| 3rd Feb 2026 7:00 am |
RNS |
Update on Saphnelo subcutaneous administration |
| 2nd Feb 2026 3:00 pm |
RNS |
Total Voting Rights |
| 2nd Feb 2026 7:05 am |
RNS |
Imfinzi recommended in EU for early gastric cancer |
| 2nd Feb 2026 7:00 am |
RNS |
AstraZeneca begins trading on NYSE |
| 30th Jan 2026 7:00 am |
RNS |
AstraZeneca agrees obesity and T2D deal with CSPC |
| 29th Jan 2026 9:51 am |
RNS |
AstraZeneca invests $15bn in China through 2030 |
| 20th Jan 2026 7:00 am |
RNS |
AstraZeneca to complete direct listing on NYSE |
| 8th Jan 2026 7:00 am |
RNS |
AZN new Head of Investor Relations Joris Silon |
| 2nd Jan 2026 3:00 pm |
RNS |
Total Voting Rights |
| 22nd Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 22nd Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 22nd Dec 2025 7:30 am |
RNS |
Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:30 am |
RNS |
Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:00 am |
RNS |
Update on LATIFY Phase III trial of ceralasertib |
| 22nd Dec 2025 7:00 am |
RNS |
Update on LATIFY Phase III trial of ceralasertib |
| 19th Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 19th Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 16th Dec 2025 7:05 am |
RNS |
Subcutaneous Saphnelo approved in EU |
| 16th Dec 2025 7:00 am |
RNS |
Enhertu approved in US for 1L HER2+ metastatic BC |
| 4th Dec 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 1st Dec 2025 3:05 pm |
RNS |
Block listing Interim Review |
| 1st Dec 2025 3:00 pm |
RNS |
Total Voting Rights |
| 26th Nov 2025 7:00 am |
RNS |
Imfinzi approved in US for early gastric cancer |
| 24th Nov 2025 7:00 am |
RNS |
AstraZeneca manufacturing investment in Maryland |
| 20th Nov 2025 7:00 am |
RNS |
Koselugo (selumetinib) approved in the US |
| 17th Nov 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 14th Nov 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 10th Nov 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 6th Nov 2025 7:00 am |
RNS |
9M and Q3 2025 results |
| 3rd Nov 2025 4:00 pm |
RNS |
Result of General Meeting |
| 3rd Nov 2025 3:00 pm |
RNS |
Total Voting Rights |
| 28th Oct 2025 7:05 am |
RNS |
Director Declaration |
| 28th Oct 2025 7:00 am |
RNS |
Koselugo (selumetinib) approved in the EU |
| 22nd Oct 2025 7:00 am |
RNS |
Tezspire Approved in EU for CRSwNP |
| 20th Oct 2025 7:05 am |
RNS |
US FDA Approves Tezspire in CRSwNP |
| 20th Oct 2025 7:00 am |
RNS |
Positive CHMP opinion for subcutaneous Saphnelo |
| 13th Oct 2025 7:00 am |
RNS |
Agreement with US Govt to lower medicine prices |
| 7th Oct 2025 7:00 am |
RNS |
Baxdrostat met primary endpoint in Bax24 Ph3 trial |
| 6th Oct 2025 7:30 am |
RNS |
Datroway improved OS and PFS in TROPION-Breast02 |
| 1st Oct 2025 3:00 pm |
RNS |
Total Voting Rights |
